Third Success from Astex Drug Discovery Pharma Collaboration and Licence Agreements as AstraZeneca Receives US Marketing Approval for Cancer Drug Truqap (capivasertib)
AstraZeneca’s Truqap™ (capivasertib) in combination with Faslodex® (fulvestrant) receives US FDA marketing approval for the treatment of adult patients with hormone receptor (HR)-positive, HER2-negative locally advanced or metastatic breast cancer with one or more biomarker alterations (PIK3CA, AKT1 or PTEN).
• Astex is eligible to receive a milestone payment and royalties on sales of the new drug under its 2005 collaboration…
Excellent to see Charles River, a Partner of One Nucleus, making progress (5 years ahead of schedule!) towards helping achieve 100% renewable electricity globally. Read more to find out how...
Arecor Therapeutics plc
(“Arecor” or the “Group”)
FIRST PRODUCT INCORPORATING ARECOR’S ARESTAT TECHNOLOGY, AT220, LAUNCHED IN EUROPE
First commercial sale triggers milestone payment and future royalties to Arecor
Cambridge, UK, 17 November 2023: Arecor Therapeutics plc (AIM: AREC), the biopharmaceutical company advancing today’s therapies to enable healthier lives, announces the triggering of a milestone payment from its global pharmaceutical partner, following the first commercial sale of a product, AT220, incorporating its proprietary Arestat™ technology platform.
Sarah Howell, Chief…
Bristol Myers Squibb's (BMS) Augtyro (repotrectinib) has been approved by the US Food and Drug Administration (FDA) to treat adult patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC).
Lung cancer is the leading cause of cancer deaths in the US, with NSCLC representing up to 85% of all lung cancer diagnoses.
More common in individuals with little to no smoking history, the ROS1 gene alteration occurs in only up to 2% of NSCLC patients and is associated with aggressive lung cancer that can often spread to the brain.
Augtyro, which is a tyrosine kinase…
The University of Glasgow and Kadans Science Partner, supported by Scottish Enterprise, are delighted to announce the construction of a new Health Innovation Hub in Govan, setting the stage for a thriving life sciences cluster in the area.
Work on the new Health Innovation Hub has begun, and is due for completion in summer 2025. Morrison Construction have been appointed as the main contractor. The Hub will attract new innovative businesses into the area, and deliver local benefits to the community through job creation.
The Hub is a flagship investment within the University’s Glasgow Riverside…
Fundraise led by Sofinnova Partners, F-Prime Capital, Digitalis Ventures and Cambridge Innovation Capital with participation from Sanofi Ventures and the University of Cambridge Venture Fund
Unique transgenic mouse platform harnesses natural power of T cells to build a portfolio of first-in-class cancer medicines
15 November 2023; Cambridge, England – T-Therapeutics (“the Company”), a biotechnology company developing next-generation TCR therapeutics designed to reshape the clinical landscape for cancer patients, today announces it has raised £48 million ($59 million) in a Series A…
Appointment of Big Pharma executive strengthens leadership team to drive ambitious growth strategy
Coventry, UK, 10 November 2023: NanoSyrinx, a synthetic biology company developing a novel platform for targeted intracellular delivery of biologic therapeutics, today announced Anthony Johnson, M. D., has joined its Board as Non-Executive Director. Tony’s appointment forms part of the Company’s ongoing strategy to expand and strengthen its leadership team as the Company prepares for the next stage in its development.
Most recently, Tony held the position of Chief Executive Officer at Goldfinch…
Tessellate BIO, an Emerging Precision Oncology Company Announces the Appointment of World-Leading Scientists to its Scientific Advisory Board
Amsterdam, the Netherlands and London, UK – 15 November 2023 - Tessellate BIO, a preclinical stage biotechnology company with a focus on novel Synthetic Lethality approaches, today announces the appointment of multiple international experts to its Scientific Advisory Board.
A key part of Tessellate BIO’s strategy is to source cutting-edge research from international world-renowned laboratories to bring into its drug discovery programs. The SAB plays an…
ViaNautis Bio announces $25 million Series A financing to drive the next generation of genetic nanomedicines
- ViaNautis’s proprietary drug delivery platform polyNaut® is designed to deliver genetic therapeutic payloads across difficult-to-penetrate biological barriers, developing new medicines for diseases with unmet clinical need
- Series A led by 4BIO Capital, BGF, and UCB Ventures with participation from the Cystic Fibrosis Foundation, Eli Lilly and Company and existing investors including Origin Capital, Meltwind and O2H
Cambridge UK, 13 November 2023 – ViaNautis…
The experienced life science logistics company, Biocair, provides critical logistics support to a cutting-edge research project into drugs that can treat, and prevent, one of the world’s more serious medical conditions, fibrosis.
Biocair is supporting the innovative, UK-based contract research company, FibroFind, to deliver precious project samples from its pre-clinical research studies to pharmaceutical companies across the world. So far, Biocair has accomplished over 100 rapid, reliable sample deliveries worldwide for FibroFind.
Fibrosis, which can affect most organs in the body, is…